research communications
Conformational changes of loops highlight a potential binding site in Rhodococcus equi VapB
aDepartment of Chemistry, Bielefeld University, Universitaetsstrasse 25, 33615 Bielefeld, Germany, and bInstitute for Cell Biology, University of Bonn, Ulrich-Haberland-Strasse 61a, 53121 Bonn, Germany
*Correspondence e-mail: hartmut.niemann@uni-bielefeld.de
Virulence-associated proteins (Vaps) contribute to the virulence of the pathogen Rhodococcus equi, but their mode of action has remained elusive. All Vaps share a conserved core of about 105 amino acids that folds into a compact eight-stranded antiparallel β-barrel with a unique topology. At the top of the barrel, four loops connect the eight β-strands. Previous Vap structures did not show concave surfaces that might serve as a ligand-binding site. Here, the structure of VapB in a new crystal form was determined at 1.71 Å resolution. The contains two molecules. In one of them, the loop regions at the top of the barrel adopt a different conformation from other Vap structures. An outward movement of the loops results in the formation of a hydrophobic cavity that might act as a ligand-binding site. This lends further support to the hypothesis that the structural similarity between Vaps and avidins suggests a potential binding function for Vaps.
Keywords: β-barrels; ligand-binding sites; conformational change; virulence factors; virulence-associated proteins; Rhodococcus equi.
PDB reference: VapB from the intracellular pathogen Rhodococcus equi, 7b1z
1. Introduction
Rhodococcus equi is a Gram-positive environmental soil bacterium that can cause severe bronchopneumonia in young foals (Vázquez-Boland & Meijer, 2019). It also poses a threat to immunocompromised humans such as AIDS patients. R. equi infects lung alveolar macrophages, where it multiplies in a remodelled compartment, the Rhodococcus-containing vacuole (Zink et al., 1987; Fernandez-Mora et al., 2005). This is an unusual phagolysosome that maintains a near-neutral pH (von Bargen et al., 2019). A virulence-associated plasmid of some 85 kbp is absolutely required for infection of foals (Takai et al., 1991; Tkachuk-Saad & Prescott, 1991) and encodes a key factor for infection and intracellular multiplication: virulence-associated protein A (VapA; Jain et al., 2003). VapA is a surface-attached 17 kDa protein that is released into the phagosome during infection and that increases the permeability of phagosome and lysosome membranes to some ions and protons (von Bargen et al., 2019). The critical activity of VapA is the collapse of the across the phagosome membrane, as chemical pH neutralization of the endocytic and phagocytic continuum using any of several pH-neutralizing drugs enables virulence-plasmid-deficient (avirulent) R. equi to multiply in macrophages. Interestingly, a proteinase K-digested version of VapA, which corresponds to the VapB fragment in this study, still has membrane-permeabilizing activity and supports intracellular multiplication of plasmid-less R. equi (von Bargen et al., 2019).
Although the membrane-binding and permeabilizing activities of VapA have been clearly documented (Wright et al., 2018; von Bargen et al., 2019), it is not known how VapA exerts its effect on membranes. The same applies to virulence-associated protein B (VapB), which is also encoded on a virulence plasmid; this plasmid is mostly absent from foal isolates and is predominantly found in porcine R. equi isolates (Ribeiro et al., 2011; Letek et al., 2008). Recent data suggest that VapB, although 78% identical to VapA in its amino-acid sequence, is not required for the virulence of VapB-producing R. equi strains (Willingham-Lane et al., 2018). It has been reported that VapB binds more weakly to yeast plasma membranes and to some liposomes than VapA does (Wright et al., 2018). However, VapB does bind well to some membranes (A. Haas. P. Hansen & J. Kniewel, unpublished data), possibly depending on their precise composition.
We reasoned that in the absence of a VapA structure and given the very high level of sequence identity (78%) of VapB to VapA, solving the structure of VapB could hint at possible membrane-interacting surfaces, which then could provide clues as to how VapA exerts its pathogenic effects (Geerds et al., 2014). Shortly after our VapB structure, the very similar structures of R. equi VapD and VapG were published (Whittingham et al., 2014; Okoko et al., 2015). Vap proteins consist of an N-terminal region that is variable in sequence and is probably intrinsically unstructured and a stably folded C-terminal core with high sequence conservation. The protease-resistant core of R. equi Vap proteins forms an eight-stranded β-barrel consisting of two Greek-key motifs. Vaps have internal symmetry, with a pseudo-twofold axis relating the two Greek-key motifs, suggesting that the structure arose by gene duplication (Whittingham et al., 2014). A short helix connects the two half-barrels, resulting in an unusual topology that is very different from the antiparallel all-next-neighbour topology typically found in (eight-stranded) β-barrels. We term the end of the barrel containing the α-helix and both termini the bottom. The top end contains the four connections between odd- and even-numbered strands, two of which are next neighbours (β1–β2 and β5–β6) and the other two of which are crossover connections (β3–β4 and β7–β8).
The Vap surface contains a flat region devoid of side chains due to the accumulation of glycines. In the VapD structure, two octyl-β-D-glucoside molecules from the crystallization solution bind to this `bald' spot that may allow R. equi Vaps to interact with large nonpolar surfaces (Whittingham et al., 2014). We had suggested a functional similarity between Vaps and avidins, which also form eight-stranded β-barrels (Geerds et al., 2014). However, avidins have a different, all-next-neighbour topology. Avidins bind biotin in a groove at the top of the molecule (Livnah et al., 1993; Weber et al., 1989). Whittingham and coworkers also noted the structural similarity between VapD and bradavidin 2, an avidin-like protein from Bradyrhizobium japonicum (Leppiniemi et al., 2013), but suggested that VapD is not involved in small-molecule binding due to the absence of a cavity (Whittingham et al., 2014). Okoko and coworkers found no significant depressions on the surfaces of VapB, VapD and VapG that would indicate the presence of a ligand-binding cavity or an enzyme active site (Okoko et al., 2015). Moreover, Okoko and coworkers noted that avidins lack crossover strands due to their antiparallel all-next-neighbour topology. As a result, the avidin barrels have intrinsically more open structures that allow one end of the barrel to develop into a ligand-binding cavity, in which the barrel interior forms the base. In contrast, Vap proteins have less potential for a binding site due to the crossover connections linking strands β3 to β4 and β7 to β8 at the top and the α-helix that seals the bottom (Okoko et al., 2015). Nevertheless, experimental data show that R. equi Vaps can interact with component(s) of the host cell, most notably membranes. Here, we present a new structure of VapB that highlights a potential binding site for a putative host cell-derived ligand.
2. Materials and methods
2.1. Macromolecule production
VapB was expressed and purified as described by Geerds et al. (2014), with some differences in the digestion with proteinase K. 50 mg VapB was digested with proteinase K (Roth, product key 7528.1) at a 25:1 protein:protease ratio in 50 ml phosphate-buffered saline for 4 h at 37°C. The protease was inactivated by adding phenylmethylsulfonyl fluoride (PMSF) to a final concentration of 2 mM and incubating on ice for 30 min. The solution was then dialyzed against 2 l 25 mM Tris pH 7, 20 mM NaCl, 0.1 mM PMSF overnight, with a protein recovery of about 50% (25.4 mg). The proteinase K digest resulted in a single VapB band on SDS–PAGE, in contrast to a previous proteinase K digest, where a double band was observed (Geerds et al., 2014). Proteinase K-digested VapB was further purified by anion-exchange on Source Q (GE Healthcare) resin equilibrated in 25 mM Tris pH 7, 20 mM NaCl. Elution with a salt gradient up to 1 M NaCl resulted in a broad and nonsymmetric peak, indicating some heterogeneity. Late peak fractions were pooled, dialyzed against 25 mM Tris pH 7.0, 20 mM NaCl overnight, concentrated to 16.8 mg ml−1 using Vivaspin concentrators, frozen in small aliquots and stored at −80°C. The recovery after proteinase K digestion and purification was about 5% (2.4 mg). Macromolecule-production information is summarized in Table 1.
‡The sequence coding for VapB is in italics, two stop codons are in bold, the NotI restriction site is underlined and the cleavage site of NotI is indicated by a vertical line. §The expressed construct comprises residues Val36–Ala197 of VapB. The additional hexahistidine tag is shown in bold. |
2.2. Crystallization
Initial crystals grew in condition F4 of The JCSG Core I Suite (20% PEG 3350, 0.2 M magnesium nitrate). The crystal used for data collection grew in a sitting-drop vapour-diffusion setup under optimized conditions (14% PEG 4000, 0.2 M magnesium nitrate) with 10 mg ml−1 protein in 25 mM Tris pH 7,0, 20 mM NaCl at 20°C using 1 µl protein solution plus 0.5 µl reservoir solution. A drop ratio of 2:1 protein:precipitant solution has been shown to yield more crystallization hits than a ratio of 1:1 or 1:2 (Ng et al., 2016), and we routinely use 2:1 drops (Niemann et al., 2006; Thoms et al., 2011; Schreiner & Niemann, 2012; Barden et al., 2014; Moritzer & Niemann, 2019; Meyer et al., 2020). The crystal grew to final dimensions of about 120 × 70 µm in about three weeks. The crystal was cryoprotected in 18% PEG 4000, 0.2 M magnesium nitrate, 20% glycerol and flash-cooled in liquid nitrogen. Crystallization information is summarized in Table 2.
|
2.3. Data collection and processing
Data were collected on beamline P14 operated by EMBL Hamburg at the PETRA III storage ring, DESY, Hamburg, Germany during setup of this beamline (on 5 October 2012) with an unfocused beam, an aperture size of 150 µm and a fixed wavelength of 1.23953 Å. The beamline was equipped with a vertical `hanging' spindle and a PILATUS 6M detector. Data were collected in two runs. After a short sweep (316 images), the detector distance was decreased to achieve higher resolution. Data were indexed and integrated with XDS (Kabsch, 2010) and both sweeps were scaled together with XSCALE using zero-dose extrapolation (Diederichs et al., 2003). Data-collection and processing statistics are summarized in Table 3.
|
2.4. Structure solution and refinement
The structure was solved by Phaser (McCoy et al., 2007) using a preliminary model of the published P6122 structure (Geerds et al., 2014) as a search model. The preliminary P6122 structure had been refined against 1.9 Å resolution home-source data before the high-resolution synchrotron data for the P6122 crystal form became available. Two copies of VapB could easily be located and the structure was manually rebuilt in Coot (Casañal et al., 2020) and refined in REFMAC5 (Murshudov et al., 2011) to facilitate quick cycles of building and Final refinements were performed in phenix.refine with TLS enabled (Liebschner et al., 2019), yielding lower R factors. Figures were generated with PyMOL. are summarized in Table 4.
in
|
3. Results and discussion
Here, we determined the structure of the protease-resistant VapB core in a new crystal form with two molecules in the et al., 2014). Here, we used a different batch of protein that may chemically differ from the previously published batch due to differences in the proteinase K digestion (see Section 2) that resulted in different behaviour of the protein in SDS–PAGE and The crystallization conditions also differ from the published conditions, which did not reproducibly yield crystals. It is unclear whether the proteinase K digestion in this work removed the C-terminal residues that were previously visible or whether these residues are present but disordered in the new structure.
The crystals diffracted to 1.71 Å resolution and the structure was solved by Electron density is visible for residues Gln86–Trp194, while three additional C-terminal residues were resolved in the published VapB structure (GeerdsThe two monomers in the a). A nitrate ion from the crystallization cocktail, which contained 200 mM magnesium nitrate, binds between strands β5 and β6 and is very well defined in the electron density (Fig. 1b). The same three residues (Asn152, Asn159 and Asn161) from both chains contribute to nitrate binding. The position and orientation of the nitrate relative to the protein is similar but not identical in chains A and B. The conformation of the asparagine side chains also differs between chains A and B, particularly for Asn159, which coordinates a nitrate O atom via its amide NH2 in chain A, while in chain B it coordinates the positively charged nitrate N atom via its amide O atom. It appears unlikely that the bound nitrate has any biological relevance. Likewise, we consider the dimeric arrangement to be a mere crystal-packing contact for several reasons: (i) it does not have C2 point-group symmetry as the vast majority of biological homodimers do (Schulz, 2010), (ii) it is not predicted to be stable in solution by the PISA server (Krissinel & Henrick, 2007), (iii) it is not present in any of the other Vap structures, even when considering all and (iv) VapG behaves as monomer in solution, as shown by multi-angle laser (Whittingham et al., 2014).
arrange around a pseudo-twofold axis (rotation of ∼176°, translation of ∼3 Å; Fig. 1An overlay of all three VapB monomers reveals that the bottom of the barrel is structurally largely invariant, while the loops at the top are flexible (Figs. 2a and 2b). An extended comparison of all available Vap structures, including VapD and VapG (Fig. 2c), shows that the structural conservation of the bottom end extends across the Vap family, with the exception of the β2–β3 loop, which differs in conformation between VapB and VapG and harbours a five-residue insertion in VapD. The conformation of the loops at the top of the barrel apparently strongly depends on the crystal-packing environment. The loops at the top of the barrel are involved in crystal-packing contacts that differ between the three crystallographically independent VapB molecules (Supplementary Fig. S1). An all-against-all analysis of the available Vap structures using the DALI server (Holm, 2020) revealed that with regard to these loops, chain A of our new VapB structure is most distant from the other Vap structures. Two of the three VapB structures (PDB entries 4cv7 and 7b1z chain B) cluster with the two VapG structures (PDB entries 5aeo chain A and 5aeo chain B). VapD (PDB entry 4csb) and VapB (PDB entry 7b1z chain A) are distinct from the VapG/VapB cluster and from each other (Fig. 3). The side chain of Tyr157 also adopts a unique rotamer in PDB entry 7b1z chain A (Fig. 2). In the first VapB structure the loops at the top of the barrel were suggested to be flexible because of their high B factors. Moreover, the β1–β2 and the β7–β8 loops were modelled with double conformations (Geerds et al., 2014). A pairwise comparison of all three VapB structures shows that the largest backbone displacements of chain A of our new structure (PDB entry 7b1z chain A) compared with the first VapB structure (PDB entry 4cv7) or chain B of the new VapB structure (PDB entry 7b1z chain B) occur in the β7–β8 loop, the β5–β6 loop and the β3–β4 loop (Fig. 4). In contrast, the β7–β8 loop has almost identical conformations in PDB entries 4cv7 and 7b1z chain B. This is reminiscent of streptavidin, in which loops connecting the eight β-strands and especially the flexible binding loop can adopt different conformations either depending on the state (unbound versus biotin-bound) or as a consequence of crystal-packing interactions (Freitag et al., 1997; Le Trong et al., 2011). Compared with the other Vap structures, the β3–β4 loop and the β7–β8 loop of PDB entry 7b1z chain A move outwards in opposite directions, creating a pocket between them. Okoko and coworkers suggested that Vap proteins may have functions that only manifest upon the conformational changes that frequently accompany the binding of small molecules to proteins (Okoko et al., 2015). Our new VapB structure reveals that despite the crossover connections, VapB can form a large cavity between the β3–β4 loop and the β7–β8 loop (Fig. 5). In all other Vap structures smaller cavities are present between the β5–β6 loop and the β7–β8 loop. The bottom of the large VapB cavity is formed by hydrophobic residues (Val96, Phe105, Phe130, Ala153, Leu158 and Ala177), while its side and mouth contain both hydrophobic (for example Ile124 and Val181) and polar (for example Ser98, Gln103, Thr123, Tyr151 and Ser179) residues. The large cavity in VapB contains 12 ordered water molecules (A311, A314, A320, A322, A332, A344, A357, A360, A380, A390, A401 and A403), giving a hint on the size and shape of a putative ligand (Fig. 6). An overlay of VapB and bradavidin 2 in complex with biotin (PDB entry 4ggz; Leppiniemi et al., 2013) using the TopMatch server (Wiederstein & Sippl, 2020) places the biotin-binding site of bradavidin 2 in roughly the same position as the cavity of VapB (Supplementary Fig. S2).
In summary, our new VapB structure suggests that the helix-capped bottom of the Vap β-barrel is structurally highly conserved and very rigid, whereas the top end is flexible. A conformational change of the loops at the top end of the VapB barrel opens a cavity that might act as binding site for a ligand. Uncovering the identity of a putative Vap ligand would substantially advance our understanding of how Vaps exert their virulence function during R. equi infections.
Supporting information
Supplementary Table and Figures. DOI: https://doi.org/10.1107/S2053230X2100738X/ow5027sup1.pdf
Acknowledgements
The synchrotron macromolecular crystallography data were collected on beamline P14 operated by EMBL Hamburg at the PETRA III storage ring, DESY, Hamburg, Germany. We would like to thank Dr Thomas Schneider and Dr Gleb Bourenkov for assistance in using the beamline. Open access funding enabled and organized by Projekt DEAL.
Funding information
AH was supported by grant HA 1929/14-1 from the Deutsche Forschungsgemeinschaft.
References
Barden, S., Schomburg, B., Conradi, J., Backert, S., Sewald, N. & Niemann, H. H. (2014). Acta Cryst. D70, 1391–1400. CrossRef IUCr Journals Google Scholar
von Bargen, K., Scraba, M., Krämer, I., Ketterer, M., Nehls, C., Krokowski, S., Repnik, U., Wittlich, M., Maaser, A., Zapka, P., Bunge, M., Schlesinger, M., Huth, G., Klees, A., Hansen, P., Jeschke, A., Bendas, G., Utermöhlen, O., Griffiths, G., Gutsmann, T., Wohlmann, J. & Haas, A. (2019). Cell. Microbiol. 21, e12958. PubMed Google Scholar
Casañal, A., Lohkamp, B. & Emsley, P. (2020). Protein Sci. 29, 1069–1078. Web of Science PubMed Google Scholar
Diederichs, K., McSweeney, S. & Ravelli, R. B. G. (2003). Acta Cryst. D59, 903–909. Web of Science CrossRef CAS IUCr Journals Google Scholar
Fernandez-Mora, E., Polidori, M., Lührmann, A., Schaible, U. E. & Haas, A. (2005). Traffic, 6, 635–653. Web of Science PubMed CAS Google Scholar
Freitag, S., Le Trong, I., Klumb, L., Stayton, P. S. & Stenkamp, R. E. (1997). Protein Sci. 6, 1157–1166. CAS PubMed Web of Science Google Scholar
Geerds, C., Wohlmann, J., Haas, A. & Niemann, H. H. (2014). Acta Cryst. F70, 866–871. CrossRef IUCr Journals Google Scholar
Holm, L. (2020). Protein Sci. 29, 128–140. Web of Science CrossRef CAS PubMed Google Scholar
Jain, S., Bloom, B. R. & Hondalus, M. K. (2003). Mol. Microbiol. 50, 115–128. Web of Science CrossRef PubMed CAS Google Scholar
Kabsch, W. (1976). Acta Cryst. A32, 922–923. CrossRef IUCr Journals Web of Science Google Scholar
Kabsch, W. (2010). Acta Cryst. D66, 125–132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Krissinel, E. & Henrick, K. (2007). J. Mol. Biol. 372, 774–797. Web of Science CrossRef PubMed CAS Google Scholar
Leppiniemi, J., Meir, A., Kähkönen, N., Kukkurainen, S., Määttä, J. A., Ojanen, M., Jänis, J., Kulomaa, M. S., Livnah, O. & Hytönen, V. P. (2013). Protein Sci. 22, 980–994. Web of Science CrossRef CAS PubMed Google Scholar
Letek, M., Ocampo-Sosa, A. A., Sanders, M., Fogarty, U., Buckley, T., Leadon, D. P., González, P., Scortti, M., Meijer, W. G., Parkhill, J., Bentley, S. & Vázquez-Boland, J. A. (2008). J. Bacteriol. 190, 5797–5805. Web of Science CrossRef PubMed CAS Google Scholar
Le Trong, I., Wang, Z., Hyre, D. E., Lybrand, T. P., Stayton, P. S. & Stenkamp, R. E. (2011). Acta Cryst. D67, 813–821. CrossRef IUCr Journals Google Scholar
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C., Urzhumtsev, A. G., Videau, L. L., Williams, C. J. & Adams, P. D. (2019). Acta Cryst. D75, 861–877. Web of Science CrossRef IUCr Journals Google Scholar
Livnah, O., Bayer, E. A., Wilchek, M. & Sussman, J. L. (1993). Proc. Natl Acad. Sci. USA, 90, 5076–5080. CrossRef CAS PubMed Web of Science Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
Meyer, T., Zumbrägel, N., Geerds, C., Gröger, H. & Niemann, H. H. (2020). Biomolecules, 10, 1130. CrossRef Google Scholar
Moritzer, A. & Niemann, H. H. (2019). Protein Sci. 28, 2112–2118. CrossRef CAS PubMed Google Scholar
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. Web of Science CrossRef CAS IUCr Journals Google Scholar
Ng, J. T., Dekker, C., Reardon, P. & von Delft, F. (2016). Acta Cryst. D72, 224–235. Web of Science CrossRef IUCr Journals Google Scholar
Niemann, H. H., Schmoldt, H., Wentzel, A., Kolmar, H. & Heinz, D. W. (2006). J. Mol. Biol. 356, 1–8. CrossRef PubMed CAS Google Scholar
Okoko, T., Blagova, E. V., Whittingham, J. L., Dover, L. G. & Wilkinson, A. J. (2015). Vet. Microbiol. 179, 42–52. CrossRef CAS PubMed Google Scholar
Ribeiro, M. G., Takai, S., Guazzelli, A., Lara, G. H. B., da Silva, A. V., Fernandes, M. C., Condas, L. A. Z., Siqueira, A. K. & Salerno, T. (2011). Res. Vet. Sci. 91, 478–481. CrossRef CAS PubMed Google Scholar
Schreiner, M. & Niemann, H. H. (2012). BMC Struct. Biol. 12, 13. Google Scholar
Schulz, G. E. (2010). J. Mol. Biol. 395, 834–843. CrossRef PubMed CAS Google Scholar
Takai, S., Sekizaki, T., Ozawa, T., Sugawara, T., Watanabe, Y. & Tsubaki, S. (1991). Infect. Immun. 59, 4056–4060. CrossRef PubMed CAS Web of Science Google Scholar
Thoms, S., Hofhuis, J., Thöing, C., Gärtner, J. & Niemann, H. H. (2011). J. Struct. Biol. 175, 362–371. Web of Science CrossRef CAS PubMed Google Scholar
Tkachuk-Saad, O. & Prescott, J. (1991). J. Clin. Microbiol. 29, 2696–2700. PubMed CAS Google Scholar
Vázquez-Boland, J. A. & Meijer, W. G. (2019). Mol. Microbiol. 112, 1–15. PubMed Google Scholar
Weber, P. C., Ohlendorf, D. H., Wendoloski, J. J. & Salemme, F. R. (1989). Science, 243, 85–88. CrossRef CAS PubMed Web of Science Google Scholar
Whittingham, J. L., Blagova, E. V., Finn, C. E., Luo, H., Miranda-CasoLuengo, R., Turkenburg, J. P., Leech, A. P., Walton, P. H., Murzin, A. G., Meijer, W. G. & Wilkinson, A. J. (2014). Acta Cryst. D70, 2139–2151. CrossRef IUCr Journals Google Scholar
Wiederstein, M. & Sippl, M. J. (2020). Nucleic Acids Res. 48, W31–W35. CrossRef CAS PubMed Google Scholar
Willingham-Lane, J. M., Coulson, G. B. & Hondalus, M. K. (2018). PLoS One, 13, e0204475. PubMed Google Scholar
Wright, L. M., Carpinone, E. M., Bennett, T. L., Hondalus, M. K. & Starai, V. J. (2018). Mol. Microbiol. 107, 428–444. CrossRef CAS PubMed Google Scholar
Zink, M. C., Yager, J. A., Prescott, J. F. & Fernando, M. A. (1987). Vet. Microbiol. 14, 295–305. CrossRef CAS PubMed Web of Science Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.